Previous 10 | Next 10 |
In this episode of Industry Focus: Wildcard , Jason Moser chats with Motley Fool analyst Brian Feroldi about three promising healthcare stocks that he personally bought. Discover their innovative products, which facilitate easy and quick diagnosis of peripheral artery disease -- plus, a "medi...
Novocure ( NVCR +5.6% ) has enrolled first patient in its Phase 2 pivotal (EF-33) trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with recurrent glioblastoma (GBM). More news on: NovoCure Limited, Healthcare stocks news, Read more .....
EF-33 will test the potential incremental survival benefit of Tumor Treating Fields delivered using high-intensity arrays in patients with recurrent glioblastoma Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor T...
Brief investment pitch This disruptive medtech player in oncology is up >7x since I started covering it on Seeking Alpha in 2016 (when it was trading at $7.76/share). I wrote the title in my initiation article as ' NovoC ure's TTFields Therapy Could Become The Standard Adjunct Therap...
The FDA designates privately held Denovo Biopharma 's lead candidate DB102 (enzastaurin) for Fast Track review for the treatment of newly diagnosed glioblastoma , an aggressive cancer of the brain or spinal cord. More news on: Eli Lilly and Company, MediciNova, Inc., ZIOPHARM Oncology,...
Novocure (NASDAQ: NVCR ) will collaborate with Merck (NYSE: MRK ) on a Phase 2 pilot study evaluating the concomitant use of Tumor Treating Fields and Keytruda (pembrolizumab) in PD-L1-positive non-small cell lung cancer (NSCLC) patients in a first-line setting. More news on: NovoCur...
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating Fields together with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for treatmen...
Apellis Reports Completion of Enrollment for Two Phase 3 Studies Apellis Pharmaceuticals Inc. ( APLS ) reported that it has completed enrollment for two of its Phase 3 studies which are DERBY and OAKS. Both the studies are designed to evaluate intravitreal pegcetacoplan for treating geog...
I'm a picky investor. I buy only the highest-quality growth stocks I can find. I look for companies that are rapidly improving their financial statements, boast a strong competitive position, have a huge growth runway ahead of them, and are trading at an attractive valuation. I believe Novo...
The last patient has been enrolled in Novocure's (NASDAQ: NVCR ) HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer. Final data collection will occur in six months. More news on: NovoCure Limited, Healt...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...